# EVOKE (semaglutide in early Alzheimer’s)

Source: https://onco.cc/trials/da-trial-evoke/  
OnCo record `da-trial-evoke` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

EVOKE tests oral semaglutide in early Alzheimer’s disease. Existing diabetes/obesity labels are not a dementia indication.

## Summary

Phase 3, randomised, placebo-controlled. Cognition outcomes and safety for Alzheimer’s use are still under study. Not for self-directed dementia treatment.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-21
- Tags: dementia-atlas
- Registry id: NCT04777396
- Phase: 3
- Setting: Early Alzheimer’s disease
- Sponsor: Novo Nordisk

## Sources

- ClinicalTrials.gov NCT04777396: https://clinicaltrials.gov/study/NCT04777396

## Connected records

- diagnoses: [Alzheimer’s disease](https://onco.cc/diagnoses/alzheimers-disease/), [Mild cognitive impairment](https://onco.cc/diagnoses/mild-cognitive-impairment/)
- drugs: [Semaglutide (EVOKE programme)](https://onco.cc/drugs/da-semaglutide-evoke/)
- companies: [Novo Nordisk](https://onco.cc/companies/da-novo/)

---
JSON: https://onco.cc/api/v1/entities/da-trial-evoke.json